muramidase and defibrotide

muramidase has been researched along with defibrotide* in 3 studies

Other Studies

3 other study(ies) available for muramidase and defibrotide

ArticleYear
Defibrotide inhibits Ca2+ dependent neutrophil activation: implications for its pharmacological activity in vascular disorders.
    Angiology, 1991, Volume: 42, Issue:12

    Defibrotide (DEF) is a polydeoxyribonucleotide agent provided with profibrinolytic and antithrombotic properties. Moreover, an antiischemic, cardioprotective effect of the drug has recently been demonstrated in experimental animals. Increasing evidence exists of the important role played by neutrophils in the development of tissue damage during chronic and acute ischemia and in the early phases of reperfusion. In order to evaluate whether the overall cytoprotective effect of DEF could be based, at least in part, on a neutrophil-involving mechanism, the authors studied the in vitro effects of the drug on human neutrophil activation triggered by several specific stimuli. The drug dose-dependently (10-100 microM) inhibited enzyme release, superoxide anion generation, and chemiluminescence induced in neutrophils by the chemoattractant oligopeptide fMLP and by the divalent cation ionophores A23187 and ionomycin. The increase of extracellular calcium concentration from 0.5 to 2.0 mM antagonized the inhibitory effect of DEF. The use of the fluorescent probe Fura 2/AM led them to show that DEF is able to reduce the cytosolic free calcium increase following specific stimulation by affecting extracellular calcium entrance. Such a behavior resembles that of calcium-antagonistic drugs, thus suggesting that DEF works, at least in part, similarly to calcium entry blockers. Such an activity on cell calcium translocation could represent the underlying molecular mechanism of cytoprotection. Finally, the inhibitory action on neutrophil functions may play a role in tissue protection during ischemic injury.

    Topics: Calcium; Dose-Response Relationship, Drug; Fibrinolytic Agents; Free Radicals; Humans; Luminescent Measurements; Muramidase; Neutrophils; Polydeoxyribonucleotides; Superoxides; Vascular Diseases

1991
Effect of defibrotide on polymorphonuclear leukocytes: modulation of calcium entry and availability.
    Seminars in thrombosis and hemostasis, 1988, Volume: 14 Suppl

    Topics: Biological Availability; Calcimycin; Calcium; Fibrinolytic Agents; Free Radicals; Humans; Muramidase; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Polydeoxyribonucleotides; Superoxides; Tetradecanoylphorbol Acetate

1988
Defibrotide in vitro inhibits neutrophil activation by a Ca++-involving mechanism.
    International journal of tissue reactions, 1987, Volume: 9, Issue:5

    Defibrotide, a polydeoxyribonucleotide provided with a pro-fibrinolytic and prostacyclin-like activity, was studied as an inhibitor of polymorphonuclear leucocyte activation in vitro. It was found capable of dose-dependently (1-8 X 10(-5) M) inhibiting FMLP-induced activation, as shown by a decrease of enzyme release and free-radical formation (superoxide anion generation and chemiluminescence). A similar inhibiting activity was observed on A23187-induced activation. An increase in extracellular Ca++ concentration significantly prevented the effect of defibrotide on ionophore stimulation. When PMA was employed as stimulating agent, the drug did not show any inhibiting effect. Finally the pre-treatment of cells with theophylline markedly reduced the inhibition by defibrotide of FMLP- and A23187-dependent activation. Since the stimulation of neutrophils by FMLP and A23187 depends on the increase of cytoplasmic free-calcium availability or extracellular calcium entrance respectively, whereas PMA activation is completely independent from any Ca++ change, the inhibiting effect of defibrotide could be attributed to a Ca++-involving mechanism.

    Topics: Calcium; Fibrinolytic Agents; Free Radicals; Humans; In Vitro Techniques; Luminescent Measurements; Muramidase; Neutrophils; Polydeoxyribonucleotides; Theophylline

1987